Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy

NCT: NCT05432232 · COMPLETED

NCT IDNCT05432232
StatusCOMPLETED
Start Date2023-03-23
Completion2025-06-06
SponsorHistoSonics, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this trial is to evaluate the technical success and safety profile of the HistoSonics Investigational System for the treatment of primary solid renal tumors.

Frequently Asked Questions

What is The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy?

The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy is a clinical trial registered under NCT05432232. Current status: COMPLETED.

What is the status of NCT05432232?

The current status of NCT05432232 (The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy) is: COMPLETED.

When did The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy start?

The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy started on 2023-03-23.

Related Devices

K233466Edison SystemHistoSonics, Inc. K241902Edison SystemHistoSonics, Inc. K252947HistoSonics® Planning ToolHistoSonics, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑